Found 44 results
Author Keyword Title Type [ Year(Asc)]
Filters: Keyword is Disease-Free Survival  [Clear All Filters]
E. Pujade-Lauraine, Hilpert, F., Weber, B., Reuss, A., Poveda, A. M., Kristensen, G. B., Sorio, R., Vergote, I. B., Witteveen, P., Bamias, A., Pereira, D., Wimberger, P., Oaknin, A., Mirza, M. Raza, Follana, P., Bollag, D., and Ray-Coquard, I., Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial., J Clin Oncol, vol. 32, no. 13, p. 1308, 2014.
A. du Bois, Floquet, A., Kim, J. - W., Rau, J., Del Campo, J. M., Friedlander, M. Leonard, Pignata, S., Fujiwara, K., Vergote, I. B., Colombo, N., Mirza, M. R., Monk, B. J., Kimmig, R., Ray-Coquard, I., Zang, R., Diaz-Padilla, I., Baumann, K. H., Mouret-Reynier, M. - A., Kim, J. - H., Kurzeder, C., Lesoin, A., Vasey, P. A., Marth, C., Canzler, U., Scambia, G., Shimada, M., Calvert, P., Pujade-Lauraine, E., Kim, B. - G., Herzog, T. J., Mitrica, I., Schade-Brittinger, C., Wang, Q., Crescenzo, R. J., and Harter, P., Incorporation of pazopanib in maintenance therapy of ovarian cancer., J Clin Oncol, vol. 32, no. 30, p. 3382, 2014.
F. Collinson, Qian, W., Fossati, R., Lissoni, A., Williams, C., Parmar, M. K. B., Ledermann, J. A., Colombo, N., and Swart, A. Marie, Optimal treatment of early-stage ovarian cancer., Ann Oncol, vol. 25, no. 6, pp. 1165-71, 2014.
T. Sugiyama, Fujiwara, K., Ohashi, Y., Yokota, H., Hatae, M., Ohno, T., Nagai, Y., Mitsuhashi, N., Ochiai, K., and Noda, K., Phase III placebo-controlled double-blind randomized trial of radiotherapy for stage IIB-IVA cervical cancer with or without immunomodulator Z-100: a JGOG study., Ann Oncol, vol. 25, no. 5, pp. 1011-7, 2014.
I. B. Vergote, Jimeno, A., Joly, F., Katsaros, D., Coens, C., Despierre, E., Marth, C., Hall, M., Steer, C. B., Colombo, N., Lesoin, A., Casado, A., Reinthaller, A., Green, J. A., Buck, M., Ray-Coquard, I., Ferrero, A., Favier, L., Reed, N. Simon, Curé, H., and Pujade-Lauraine, E., Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a EORTC GCG, and GCIG study., J Clin Oncol, vol. 32, no. 4, pp. 320-6, 2014.
K. Ushijima, Kamura, T., Tamura, K., Kuzuya, K., Sugiyama, T., Noda, K., and Ochiai, K., Docetaxel/irinotecan combination chemotherapy in platinum/taxane-refractory and -resistant ovarian cancer: JGOG/WJGOG Intergroup Study., Int J Clin Oncol, vol. 18, no. 1, pp. 126-31, 2013.
F. Heitz, du Bois, A., Harter, P., Lubbe, D., Kurzeder, C., Vergote, I. B., Plante, M., and Pfisterer, J., Impact of beta blocker medication in patients with platinum sensitive recurrent ovarian cancer-a combined analysis of 2 prospective multicenter trials by the AGO Study Group, NCIC-CTG and EORTC-GCG., Gynecol Oncol, vol. 129, no. 3, pp. 463-6, 2013.
B. J. Monk, Pujade-Lauraine, E., and Burger, R. A., Integrating bevacizumab into the management of epithelial ovarian cancer: the controversy of front-line versus recurrent disease., Ann Oncol, vol. 24 Suppl 10, p. x58, 2013.
S. Banerjee, Rustin, G. J. S., Paul, J., Williams, C., Pledge, S., Gabra, H., Skailes, G., Lamont, A., Hindley, A., Goss, G., Gilby, E., Hogg, M., Harper, P., Kipps, E., Lewsley, L. A., Hall, M., Vasey, P. A., and Kaye, S. B., A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG., Ann Oncol, vol. 24, no. 3, p. 687, 2013.
F. A. Raja, Counsell, N., Colombo, N., Pfisterer, J., du Bois, A., Parmar, M. K. B., Vergote, I. B., Gonzalez-Martin, A., Alberts, D. S., Plante, M., Torri, V., and Ledermann, J. A., Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data., Ann Oncol, vol. 24, no. 12, pp. 3028-34, 2013.
C. Khoon Lee, Simes, R. J., Brown, C., Gebski, V., Pfisterer, J., Swart, A. Marie, Berton-Rigaud, D., Plante, M., Skeie-Jensen, T., Vergote, I. B., Schauer, C., Pisano, C., Parma, G., Baumann, K. H., Ledermann, J. A., Pujade-Lauraine, E., Bentley, J., Kristensen, G. B., Belau, A., Nankivell, M., Canzler, U., Lord, S. J., Kurzeder, C., and Friedlander, M. Leonard, A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer., Ann Oncol, vol. 24, no. 4, p. 943, 2013.
E. Greimel, Kristensen, G. B., van der Burg, M. E. L., Coronado, P., Rustin, G. J. S., del Rio, A. Sanchez, Reed, N. Simon, Nordal, R. R., Coens, C., and Vergote, I. B., Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy., Gynecol Oncol, vol. 131, no. 2, pp. 437-44, 2013.
D. Stark, Nankivell, M., Pujade-Lauraine, E., Kristensen, G. B., Elit, L., Stockler, M., Hilpert, F., Cervantes, A., Brown, J., Lanceley, A., Velikova, G., Sabate, E., Pfisterer, J., Carey, M. S., Beale, P., Qian, W., Swart, A. Marie, Oza, A. M., and Perren, T. J., Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial., Lancet Oncol, vol. 14, no. 3, p. 243, 2013.
B. You, Colomban, O., Heywood, M., Lee, C., Davy, M., Reed, N. Simon, Pignata, S., Varsellona, N., Emons, G., Rehman, K., Steffensen, K. Dahl, Reinthaller, A., Pujade-Lauraine, E., and Oza, A. M., The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: data from CALYPSO trial (a GINECO-GCIG study)., Gynecol Oncol, vol. 130, no. 2, p. 294, 2013.
T. J. Herzog, Vermorken, J. B., Pujade-Lauraine, E., Provencher, D. M., Jagiello-Gruszfeld, A., Kong, B., Boman, K., Park, Y. Choi, Parekh, T., Lebedinsky, C., Gómez, J., and Monk, B. J., Correlation between CA-125 serum level and response by RECIST in a phase III recurrent ovarian cancer study., Gynecol Oncol, vol. 122, no. 2, pp. 350-5, 2011.
S. Kumagai, Sugiyama, T., Shoji, T., Michimae, H., Katsumata, N., Aoki, D., Terauchi, F., Jobo, T., Ochiai, K., and Yasuda, M., Does severe anemia caused by dose-dense paclitaxel-Carboplatin combination therapy have an effect on the survival of patients with epithelial ovarian cancer? Retrospective analysis of the Japanese gynecologic oncology group 3016 trial., Int J Gynecol Cancer, vol. 21, no. 9, pp. 1585-91, 2011.
T. J. Perren, Swart, A. Marie, Pfisterer, J., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G. B., Carey, M. S., Beale, P., Cervantes, A., Kurzeder, C., du Bois, A., Sehouli, J., Kimmig, R., Stähle, A., Collinson, F., Essapen, S., Gourley, C., Lortholary, A., Selle, F., Mirza, M. R., Leminen, A., Plante, M., Stark, D., Qian, W., Parmar, M. K. B., and Oza, A. M., A phase 3 trial of bevacizumab in ovarian cancer., N Engl J Med, vol. 365, no. 26, p. 2496, 2011.
C. Khoon Lee, Simes, R. J., Brown, C., Lord, S., Wagner, U., Plante, M., Vergote, I. B., Pisano, C., Parma, G., Burges, A., Bourgeois, H., Högberg, T., Bentley, J., Angleitner-Boubenizek, L., Ferrero, A., Richter, B., Hirte, H., Gebski, V., Pfisterer, J., Pujade-Lauraine, E., and Friedlander, M. Leonard, Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer., Br J Cancer, vol. 105, no. 8, pp. 1144-50, 2011.